Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C] Antaitavir Hasophate
NCT05446233Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of antaitavir hasophate in hepatitis C (HCV), sponsored by Sunshine Lake Pharma. Primary endpoints: Distribution ratio of total radioactivity in whole blood and plasma of [14C] Antaitavir Hasophate at 15 days and Cumulative excretion of [14C] Antaitavir Hasophate -related material at 15 days. Started Nov 2022; status: completed.
02
Drugs
antaitavir hasophate
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05446233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446233.